Cholesteryl ester transfer protein inhibitors

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 5, 2001, Pages 739-745

  Shinkai, H ^a  

^a JT Inc   (Japan)

Author keywords

Cholesteryl ester transfer protein (CETP); Coronary heart disease (CHD); High density lipoprotein (HDL); Reverse cholesterol transport (RCT)

Indexed keywords

1,2,3,4 TETRAHYDROQUINOLINE DERIVATIVE; 2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; 4 PHENYL 5 TRIDECYL 4H 1,2,4 TRIAZOLE 3 THIOL; AMINOALCOHOL; AMINOALCOHOL DERIVATIVE; BM 99 3; CGS 25159; CHLOROPUUPEHENONE; CHOLESTEROL DERIVATIVE; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; ERABULENOL A; ERABULENOL B; FIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NATURAL PRODUCT; NICOTINIC ACID; PROTEIN INHIBITOR; SC 795; SCLERODEROLIDE; SIMVASTATIN; SULFUR DERIVATIVE; TETRALIN DERIVATIVE; TRIACYLGLYCEROL; TRIAZINE; TRIFLUORO 3 AMINO 2 PROPANOL; U 95594; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; WIEDENDIOL A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG ISOLATION; DRUG PROTEIN BINDING; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; NONHUMAN; REVIEW; RISK FACTOR;

EID: 0035004144     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.5.739     Document Type: Review

References (47)

1. Drug treatment of lipid disorders
2. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
3. High-density lipoprotein - The clinical implications of recent studies
4. Atherosclerosis
5. Molecular physiology of reverse cholesterol transport
6. Molecular mechanisms of reverse cholesterol transport
7. Paraoxonase - Genes and disease
8. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis
9. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia
10. Extended-release niacin vs. gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-gemfibrozil study group
11. Lecithin: Cholesterol acyltransferase overexpression generates hyperalphalipoproteinemia and a non-atherogenic lipoprotein pattern in transgenic rabbits
12. Influence of lipoprotein lipase and hepatic lipase on the transformation of VLDL and HDL during lipolysis of VLDL
13. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice
14. The arg 123 - Tyr 166 central domain of human apoAI is critical for lecithin: Cholesterol acyl transferase-induced hyperalphalipoproteinemia and HDL remodeling in transgenic mice
15. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse
16. Plasma cholesterol ester transfer protein
17. Regulation of cholesteryl ester transfer protein (CETP) activity: Review of in vitro and in vivo studies
18. Plasma lipid transfer proteins, high-density lipoproteins and reverse cholesterol transport
19. Cholesteryl ester transfer protein: Friend or foe?
20. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene
21. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels
22. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein
23. Plasma lipid transfer protein as a determination of the atherogenicity of monkey plasma lipoproteins
24. Increased transfer of cholesteryl esters from high-density lipoproteins to low-density and very low-density lipoproteins in patients with angiographic evidence of coronary artery disease
25. Relationship of high-density lipoprotein subfractions and cholesteryl ester transfer protein in plasma to carotid artery wall thickness
26. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis
27. Kinetics and inhibition of lipid exchange catalyzed by plasma cholesteryl ester transfer protein (lipid transfer protein)
28. Inhibition of cholesteryl ester transfer protein by apolipoproteins, lipopolysaccharides and cholesteryl sulfate
29. Wiedendiol-A and -B, cholesterylester transfer protein inhibitors from the marine sponge Xestospongia wiedenmayeri
30. Inhibition of cholesterol ester transfer protein by CGS 25159 and changes in lipoproteins in hamsters
31. Erabulenols, inhibitors of cholesteryl ester transfer protein produced by Penicillium sp. FO-5637. I. Production, isolation and biological properties
32. Structure-specific inhibition of cholesteryl ester transfer protein by azaphilones
33. Discovery, isolation, structure elucidation and biosynthesis of U-106305, a cholesteryl ester transfer protein inhibitor from UC 11136
34. KRIBB-BP005m: A new inhibitor of cholesteryl ester transfer protein (CETP) produced from Trichothecium roseum F1064
35. CETP inhibitory activity of ceramides, isolated from the Gorgonian acabraria undulata
36. Inactivation of cholesteryl ester transfer protein by cysteine modification
37. Cholesteryl ester transfer protein inhibition by PD 140195
38. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
39. Bis(2-(acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols and S-(2-(acylamino)-phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein
40. Monoclonal antibody inhibition of cholesteryl ester transfer protein activity in the rabbit
41. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis
42. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits
43. Substituted 1,3,5-triazines as cholesteryl ester transfer protein inhibitors
44. Discovery of chiral N,N-disubstituted trifluoro-3-amino-2-propanols as potent inhibitors of cholesteryl ester transfer protein
45. Stereospecific inhibition of CETP by chiral N,N-disubstituted trifluoro-3-amino-2-propanols
46. Distribution of lipid in 8,500 men with coronary artery disease
47. Cholesteryl ester transfer protein as a potential therapeutic target to improve the HDL cholesterol ratio